Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis
23.12.2021 17:06:00 EET | Business Wire | Press release
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an agreement with Enzene Biosciences Limited to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialised from 2026 in Europe, the UK, Switzerland, and Australia.
Theramex’s Tocilizumab product will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors. The reference product RoActemra® is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate; moderate to severe RA adult patients who have not responded well/intolerant to DMARDs or Anti-TNFs; active systemic juvenile idiopathic arthritis in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids; juvenile idiopathic polyarthritis in patients 2 years of age and older unresponsive to MTX; treatment of Giant Cell Arteritis in adults; and chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.
Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. There may be periods where symptoms become worse, known as flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints. Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
“Rheumatoid arthritis affects more women than men, so the addition of this biosimilar drug to our existing Rheumatology portfolio continues our strategic determination to improve access and affordability of important treatments for women. We are excited to expand our focus in Rheumatology to now include rheumatoid arthritis to help even more patients with bone diseases and joint pain”, said Theramex CEO Robert Stewart .
Dr. Himanshu Gadgil, Enzene's Whole Time Director said, "The development of Enzene’s Tocilizumab, through our innovative efforts in the manufacturing of monoclonal antibodies, marks another highlight in a series of endeavours driven by our mission to provide affordable and expanded access to crucial medicines. Our partnership with Theramex bolsters our mission to bring affordable healthcare to patients across the world”.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
About Enzene Biosciences Ltd.
Enzene is an innovation-driven biotech company, a subsidiary of Alkem Laboratories Ltd. (One of the top five pharmaceutical companies in India*) located in Pune, India. Enzene's focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services.
(*as per the latest IQVIA data of MAT July 2021)
For more information on Enzene Biosciences Ltd., please visit www.enzene.com
For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com
1 https://www.nhs.uk/conditions/rheumatoid-arthritis/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005258/en/
Contact information
Theramex
Jesús López | Associate Director, Communication & Digital | Jesus.Lopez@Theramex.com
Enzene Biosciences Ltd.
For media enquiries,
Dr. Tarun Chawla
Head - Business Development & Business Operations
Enzene Biosciences Ltd.
For any further enquiries, please reach out to: bd@enzene.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aurora Solar Adds Integrated Storage Modeling to HelioScope, Uniting Commercial Solar Design, Storage, and Financial Analysis in One Solution16.6.2026 13:00:00 EEST | Press release
Aurora Solar, the leading global platform for solar sales and design, today announced the addition of integrated storage modeling to HelioScope. This new feature empowers users to size storage, model performance, and run the financial case in the same place they design the system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616352623/en/ A preview of how storage modeling is integrated into the design workflow in HelioScope for fast iteration and optimization of solar-plus-storage projects What once required three tools — design, storage modeling, financials — now happens in one solution, from layout to a lender-ready output developers can take straight into financing. When a client asks what a bigger battery does to the economics, the answer takes minutes, not days. "The solar market is being tested right now, and the companies that come out ahead will be the ones that make their teams faster and their numbers more def
Dubai Chambers Organises Open Dialogue in London to Showcase Dubai’s Competitive Advantages as a Global Business Hub16.6.2026 12:25:00 EEST | Press release
Dubai Chambers organised an open dialogue in London in cooperation with the London Chamber of Commerce and Industry (LCCI) aimed at showcasing Dubai’s competitive advantages as a global business hub to a group of leading British investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616827193/en/ H.E. Mohammad Ali Rashed Lootah addresses the audience during the event (Photo: AETOSWire) The event was attended by His Excellency Mohammad Ali Rashed Lootah, President and CEO of Dubai Chambers, together with UK business leaders. Discussions highlighted the key investment opportunities Dubai offers across diverse sectors, as well as the city’s advantages as a hub for the expansion of British companies in the region and globally. The session also outlined the comprehensive support provided by Dubai Chambers to UK investors to ensure the smooth establishment and growth of their businesses in Dubai. The discussions explored how
NIQ and Unlimitail Collaborate to Deliver the Next Generation of Omnichannel Retail Media Insights & Measurement Across Retailers and Countries16.6.2026 12:00:00 EEST | Press release
Retail media investment is accelerating globally, with 67% of CMOs planning to increase spending on retail media networks (RMNs) in 2026. Yet only 53% believe today's RMNs provide adequate measurement and attribution capabilities, highlighting a critical gap in proving true business impact across retailers and markets.* Today, NIQ (NYSE: NIQ), a leading consumer intelligence company, and Unlimitail, a leading retail media network, announced a strategic collaboration designed to help brands and retailers unlock a new era of retail media accountability through advanced measurement, consumer insights, interoperable data infrastructure, and AI-powered analytics. This collaboration will combine Unlimitail's extensive retail media network, which spans 21 countries, 35 retailers, more than 120 retailer websites, and over 250 million loyalty cardholders, with NIQ's industry-leading measurement, analytics, and consumer intelligence capabilities. Together, the companies will help advertisers mov
Thredd Expands Partnership with ID DISTRIBUTION to Power Next Phase of Employee Benefits and Expense Innovation16.6.2026 12:00:00 EEST | Press release
Thredd, the AI-first issuer processing platform, today announced an expanded partnership with ID DISTRIBUTIONthrough its flagship program Vaziva, a leading employee benefits and payments platform, to support its growth beyond consumer payments, into corporate payments, as well as their international expansion. Thredd has worked with ID DISTRIBUTIONsince 2020, supporting the company’s consumer offering in France with physical and digital card issuing and payments processing capabilities. Its Vaziva card program enables companies to digitally manage and distribute multiple types of employee benefits through a single prepaid Mastercard-branded card experience. The program supports convenient, secure card usage for employees to access and use benefits across categories including lunch, gifts, culture, holidays, and travel. With more employers seeking simpler, more digital ways to manage employee benefits and purchasing, IDD is building on its existing consumer card programme to launch a ne
Respond.io Raises $62.5M Series B to Scale AI-Powered Customer Conversations Into North America and Europe16.6.2026 11:00:00 EEST | Press release
Respond.io, a customer conversation management platform, today announced a $62.5 million Series B round led by Camber Partners, with participation from Endeavor Catalyst and existing investors. What respond.io does Respond.io enables mid-market B2C businesses to grow revenue from high volumes of customer chats and calls. It unifies WhatsApp, Instagram, TikTok, Messenger, LINE, Telegram, WeChat, voice calls, email, web chat and 16 more integrations into a single platform with AI agents, automation, and CRMs. This turns fragmented customer conversations into a measurable revenue engine, purpose-built for real-world scale and complexity. The company serves industries where customers initiate conversations before buying, booking, or committing, including education, healthcare, automotive, retail and travel. The platform powers 2 billion messages per quarter for more than 10,000 businesses in over 180 countries, including Toyota, British Airways, Radisson, Hertz, and Decathlon. Respond.io g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom